ATE420873T1 - Chemokin rezeptor bindenden heterozyklische verbindungen - Google Patents

Chemokin rezeptor bindenden heterozyklische verbindungen

Info

Publication number
ATE420873T1
ATE420873T1 AT01973887T AT01973887T ATE420873T1 AT E420873 T1 ATE420873 T1 AT E420873T1 AT 01973887 T AT01973887 T AT 01973887T AT 01973887 T AT01973887 T AT 01973887T AT E420873 T1 ATE420873 T1 AT E420873T1
Authority
AT
Austria
Prior art keywords
chemokine receptor
receptor binding
heterocyclic compounds
binding heterocyclic
multiplicity
Prior art date
Application number
AT01973887T
Other languages
English (en)
Inventor
Gary Bridger
Renato Skerlj
Al Kaller
Curtis Harwig
David Bogucki
Trevor Wilson
Jason Crawford
Ernest Mceachern
Bem Atsma
Siqiao Nan
Yuanxi Zhou
Dominique Schols
Christopher Smith
Fluri Rosaria Di
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of ATE420873T1 publication Critical patent/ATE420873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
AT01973887T 2000-09-15 2001-09-17 Chemokin rezeptor bindenden heterozyklische verbindungen ATE420873T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23308700P 2000-09-15 2000-09-15
US23481600P 2000-09-22 2000-09-22

Publications (1)

Publication Number Publication Date
ATE420873T1 true ATE420873T1 (de) 2009-01-15

Family

ID=26926617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973887T ATE420873T1 (de) 2000-09-15 2001-09-17 Chemokin rezeptor bindenden heterozyklische verbindungen

Country Status (18)

Country Link
US (3) US6835731B2 (de)
EP (1) EP1317443B1 (de)
JP (1) JP2004508421A (de)
KR (1) KR20030029997A (de)
CN (1) CN1237061C (de)
AT (1) ATE420873T1 (de)
AU (2) AU9355101A (de)
BR (1) BR0113931A (de)
CA (1) CA2419219A1 (de)
DE (1) DE60137435D1 (de)
HU (1) HUP0301094A2 (de)
IL (1) IL154228A0 (de)
MX (1) MXPA03002325A (de)
NO (1) NO20031178D0 (de)
NZ (1) NZ524421A (de)
PL (1) PL360141A1 (de)
SG (1) SG126006A1 (de)
WO (1) WO2002022599A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
MXPA03002325A (es) * 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
US7141590B2 (en) 2000-12-29 2006-11-28 Ucb Sa Pharmaceutical uses and synthesis of nicotinanilide-N-oxides
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
KR100996378B1 (ko) 2001-07-31 2010-11-25 아노르메드 인코포레이티드 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
IL161784A0 (en) 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
RU2005102004A (ru) 2002-06-27 2005-10-20 Шеринг Акциенгезельшафт (De) Замещенные хинолины как антагонисты рецептора ccr5
JP4666256B2 (ja) 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
EP1613613B1 (de) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4-chemokinrezeptor-bindende verbindungen
ES2393188T3 (es) 2003-04-22 2012-12-19 Genzyme Corporation Compuestos heterocíclicos que se unen a los receptores de quimiocina y presentan eficacia mejorada
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
JP4795022B2 (ja) * 2003-09-30 2011-10-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗真菌剤
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
WO2005059107A2 (en) 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
JP4916889B2 (ja) * 2004-02-03 2012-04-18 ケモセントリックス インコーポレーティッド 血管新生を調節するための方法および組成物
MX2007001514A (es) * 2004-08-02 2007-03-27 Smithkline Beecham Corp Compuestos quimicos.
JPWO2006016548A1 (ja) * 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
EP1796716A4 (de) * 2004-08-13 2010-09-08 Anormed Inc Chemokin-kombinationen zur mobilisierung von vorläufer/stammzellen
MX2007001958A (es) * 2004-08-16 2007-05-09 Smithkline Beecham Corp Compuestos quimicos.
EP1790639B1 (de) 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclische verbindungen und ihre verwendung als cxcr4-antagonisten
EP1799671A4 (de) * 2004-09-02 2009-06-10 Smithkline Beecham Corp Chemische verbindungen
BRPI0515594B8 (pt) 2004-09-22 2021-05-25 Janssen Pharmaceutica Nv compostos inibidores da interação entre mdm2 e p53,composição farmacêutica, processo para a preparação desta composição farmacêutica, usos dos compostos, suas combinações e processo para a preparação destes compostos
EP1793825A4 (de) * 2004-09-24 2009-12-09 Smithkline Beecham Corp Chemische verbindungen
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
JP2008524255A (ja) * 2004-12-17 2008-07-10 スミスクライン ビーチャム コーポレーション 化学物質
JP2008535779A (ja) * 2005-01-07 2008-09-04 エモリー・ユニバーシテイ Ｈｉｖ感染治療のためのｃｘｃｒ４拮抗薬
EP1849765A4 (de) * 2005-02-02 2010-05-05 Ajinomoto Kk Verfahren zur herstellung einer pyrimidinverbindung
US8680092B2 (en) 2005-02-25 2014-03-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and medicinal use thereof
JP4874958B2 (ja) * 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
CA2649253A1 (en) * 2005-05-25 2006-11-30 Hadasit Medical Research Services & Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
JP2008543858A (ja) 2005-06-15 2008-12-04 ジェンザイム・コーポレーション ケモカインレセプター結合化合物
EP1904501A2 (de) * 2005-07-11 2008-04-02 Smithkline Beecham Corporation Chemische verbindungen
CN101365336B (zh) 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP5217438B2 (ja) * 2005-11-18 2013-06-19 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
EP1984375A2 (de) * 2006-01-25 2008-10-29 Smithkline Beecham Corporation Chemische verbindungen
AR059197A1 (es) * 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
WO2008029276A2 (en) 2006-02-02 2008-03-13 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
CA2644649C (en) 2006-03-22 2014-06-17 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
BRPI0714799A2 (pt) * 2006-08-02 2013-05-21 Genzyme Corp terapia de combinaÇço
EP2065377B1 (de) * 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Durch einen heteroarylring substituiertes pyridinderivat und antipilzmittel, das dieses enthält
US8034921B2 (en) 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN102702185A (zh) * 2007-04-27 2012-10-03 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐的结晶
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
TW200922557A (en) 2007-08-06 2009-06-01 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
DK2262808T3 (da) 2008-03-28 2013-11-04 Altiris Therapeutics Chemokinreceptormodulatorer
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
NZ594186A (en) 2009-02-04 2012-12-21 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
JP2012176900A (ja) * 2009-06-24 2012-09-13 Eisai R & D Management Co Ltd （（ホスホノオキシ）メチル）ピリジニウム環を有するピリジン誘導体およびそれらを含有する抗真菌剤
US20120225862A1 (en) 2009-07-21 2012-09-06 Auckland Univservices Limited Heteroaryl benzamides, compositions and methods of use
LT2509619T (lt) 2009-12-11 2021-04-12 Medregen, Llc Gydymo būdai, naudojant kamieninių ląstelių mobilizatorius ir imunosupresijos agentus
WO2011119738A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Methods of treatment using stem cell mobilizers
GB201005511D0 (en) * 2010-03-31 2010-05-19 Takeda Pharmaceutical Compounds and their use
EP2627324A4 (de) 2010-10-11 2014-05-07 Univ Leland Stanford Junior Substituierte benzamide und verwendungen davon
US9079859B2 (en) 2011-01-21 2015-07-14 Auckland Uniservices Limited Synthetic lethal targeting of glucose transport
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
SG10201509063SA (en) * 2012-04-12 2015-12-30 Univ Leland Stanford Junior Substituted benzamides and their uses
US9316666B2 (en) 2012-11-27 2016-04-19 Murata Manufacturing Co., Ltd. Acceleration sensor having a capacitor array located in the center of an inertial mass
CN105358531B (zh) * 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
ES2927803T3 (es) 2013-04-29 2022-11-11 Medregen Llc Curación de heridas mediante la movilización de células madre autólogas
AU2016269839B2 (en) 2015-06-03 2021-07-08 The University Of Queensland Mobilizing agents and uses therefor
CA3002418C (en) 2015-10-23 2023-10-03 Vifor (International) Ag Novel ferroportin inhibitors
EP3389634B1 (de) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Verfahren zur behandlung von krebs
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3808748A1 (de) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituierte piperidine als cxcr4-inhibitoren
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20220251108A1 (en) 2019-01-23 2022-08-11 The Johns Hopkins University Non-immunosuppressive fk506 analogs and use thereof
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
US20210008161A1 (en) 2019-06-17 2021-01-14 Crispr Therapeutics Ag Methods and compositions for improved homology directed repair
CA3146375A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents
US20220228142A1 (en) 2020-12-17 2022-07-21 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
US6172061B1 (en) * 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
JPH11269146A (ja) * 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
EP1072263A4 (de) * 1998-03-26 2004-03-31 Japan Tobacco Inc Amidderivate und nociceptinantagonisten
SE512225C2 (sv) 1998-06-26 2000-02-14 Jouko Haverinen Fixtur
WO2000042852A1 (en) * 1999-01-25 2000-07-27 Smithkline Beecham Corporation Compounds and methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6362201B1 (en) * 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
AU775123B2 (en) * 1999-03-24 2004-07-15 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
MXPA03002325A (es) * 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.

Also Published As

Publication number Publication date
EP1317443B1 (de) 2009-01-14
IL154228A0 (en) 2003-07-31
AU9355101A (en) 2002-03-26
US20080090846A1 (en) 2008-04-17
WO2002022599A3 (en) 2002-05-30
WO2002022599A2 (en) 2002-03-21
US6835731B2 (en) 2004-12-28
CA2419219A1 (en) 2002-03-21
EP1317443A2 (de) 2003-06-11
AU2001293551B8 (en) 2002-03-26
AU2001293551B2 (en) 2007-08-23
US20020147192A1 (en) 2002-10-10
JP2004508421A (ja) 2004-03-18
MXPA03002325A (es) 2003-06-24
BR0113931A (pt) 2004-01-13
CN1458929A (zh) 2003-11-26
NO20031178L (no) 2003-03-14
DE60137435D1 (de) 2009-03-05
PL360141A1 (en) 2004-09-06
US7312234B2 (en) 2007-12-25
HUP0301094A2 (hu) 2003-09-29
CN1237061C (zh) 2006-01-18
US20050026942A1 (en) 2005-02-03
SG126006A1 (en) 2006-10-30
NO20031178D0 (no) 2003-03-14
NZ524421A (en) 2005-02-25
KR20030029997A (ko) 2003-04-16

Similar Documents

Publication Publication Date Title
ATE420873T1 (de) Chemokin rezeptor bindenden heterozyklische verbindungen
ATE327988T1 (de) Chemokine rezeptor bindende heterozyklische verbindungen
ATE338461T1 (de) Pyrazolpyrimidinfungizide
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
MXPA05011597A (es) Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
ATE425157T1 (de) Chemokin rezeptor bindenden heterozyklische verbindungen
SE9904652D0 (sv) Novel Compounds
ATE335733T1 (de) Chemokin rezeptor bindenden heterozyklischen verbindungen
DK2264172T3 (da) Oligomerforbindelser til modulering af HIF-1á-ekspression
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
SG155941A1 (en) Inhibitors of the interaction between mdm2 and p53
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
YU75601A (sh) Postupak za pripremanje modulatora nesteroidnih glukokortikoidnih receptora
ATE407122T1 (de) Azadecalinmodulatoren des glucocorticoidrezeptors
DE60136667D1 (de) Präzisionsträgerplatte
NO20021409D0 (no) Hastighets-kontrollerte partikler
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
DK1347984T3 (da) Fremgangsmåde til fremstilling af taxanderivater
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
DK1280752T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-chlorphenoler
ATE343390T1 (de) Kalzilytische verbindungen
NO20024679D0 (no) Krystallinsk farmasöytikum
DK1660463T3 (da) Fremgangsmåde til fremstilling af phenyltetrazolderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties